High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates.

Jihad Said Inshasi, Abubaker Almadani, Sarmad Al Fahad, Suzan Ibrahim Noori, Taoufik Alsaadi, Mustafa Shakra, Ahmed Osman Shatila, Tayseer Mohammed Zein, Amir Boshra

Neurodegenerative disease management 2020 Aug

filter terms:

The number of disease-modifying treatments (DMDs) for relapsing-remitting multiple sclerosis has increased. DMDs differ not only in their efficacy and safety/tolerability, but also in the treatment burden of, associated with their initiation, route/frequency of administration, maintenance treatment and monitoring. High-efficacy DMDs bring the prospect of improved suppression of relapses and progression of disability, but may have serious safety issues, and burdensome long-term monitoring. Studies of patient preferences in this area have focused on side effects, efficacy and route of administration. Adherence to DMDs is often suboptimal in relapsing-remitting multiple sclerosis and there is a need to understand more about how the complex therapeutic and administration profiles of newer DMDs interact with these barriers to support optimal adherence to therapy.

Citation

Jihad Said Inshasi, Abubaker Almadani, Sarmad Al Fahad, Suzan Ibrahim Noori, Taoufik Alsaadi, Mustafa Shakra, Ahmed Osman Shatila, Tayseer Mohammed Zein, Amir Boshra. High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates. Neurodegenerative disease management. 2020 Aug;10(4):257-266